Abhishesh Kumar Mehata
M. Pharm., Ph.D. in Pharmaceutics, from IIT BHU, India & Postdoc from UC Davis, USA.
M. Pharm., Ph.D. in Pharmaceutics, from IIT BHU, India & Postdoc from UC Davis, USA.
My research focuses on the development of targeted nanomedicine, nanotheranostics, and biomaterial-based therapeutics for cancer and precision medicine. I bridge the gap between materials science and tumor biology to create smart, next-generation treatments that are both highly effective and safe for patients.During my Ph.D., my work centered on designing targeted nanomedicine and nanotheranostics specifically for breast cancer imaging and therapy. Through this research, I gained extensive, hands-on expertise in the entire lifecycle of advanced drug delivery systems. This includes everything from the initial chemical design and synthesis to deep physical characterization and rigorous biological testing.
My research interests encompass the development of innovative nanocarriers for targeted drug delivery, molecular imaging, cancer biology, immunotherapy, and precision medicine. I have extensive experience in the fabrication and characterization of polymeric nanoparticles, lipid nanoparticles, solid lipid nanoparticles, liposomes, liquid crystalline nanoparticles, cubosomes, exosomes, metallic nanoparticles (Ag, Au, Ag-Au, CuS, etc.), and ultrasmall fluorescent nanoclusters. My expertise also includes physicochemical characterization, bioanalytical HPLC method development and validation, in vitro cell-based assays, pharmacokinetic studies, and in vivo efficacy and safety evaluation in preclinical animal models, along with statistical data analysis.
Currently, as a Postdoctoral Scholar in the Department of Dermatology at the University of California, Davis, my research focuses on developing peptide-based therapeutics and targeted nanoparticle platforms for colorectal cancer. My work is centered on engineering targeted polymeric nanoparticles for the intracellular delivery of therapeutic peptides that disrupt oncogenic signaling pathways, particularly c-MYC-driven tumor progression. I employ multidisciplinary approaches combining nanotechnology, molecular biology, cancer biology, transcriptomics, single-cell RNA sequencing, and preclinical animal models to elucidate therapeutic mechanisms and accelerate the development of next-generation precision cancer therapeutics.
My long-term research goal is to develop clinically translatable nanomedicine platforms that integrate targeted drug delivery, molecular imaging, and precision therapeutics to improve the diagnosis and treatment of cancer.
Biomaterials, Drug Delivery, Targeted Therapy, Diagnosis, Cancer Biology, and Preclinical Testing
PLGA Nanoplatform for the Hypoxic Tumor Delivery: Folate Targeting, Therapy, and Ultrasound/Photoacoustic Imaging. Mehata et al, 2024, ACS Applied Bio materials.
Next-Generation Anticancer Peptides: Engineering, Nanotheranostics and Clinical Translation. Mehata et al. 2026, Nanotheranostics